期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Trim22缺失突变体真核表达载体的构建 被引量：1

Construction of eukaryotic expression vector for truncation mutants of Trim22
下载PDF
导出
摘要 目的构建Trim22缺失突变体的真核表达载体,为进一步研究Trim22与HIV-1衣壳蛋白的相互作用奠定基础。方法以野生型Trim22真核表达质粒为模板,用PCR方法扩增出5种类型Trim22缺失突变体的基因片段,克隆到5`-Flag-pcDNA3.1(+)真核表达载体,通过酶切、菌落PCR及测序进行鉴定。将该载体转染HEK293T细胞,用蛋白印迹及免疫沉淀检测Trim22缺失突变体的蛋白表达。结果通过酶切、PCR及测序鉴定,成功构建5种人Trim22缺失突变体的表达载体,载体均可以在HEK293T细胞中表达。结论成功构建5种人Trim22缺失突变体的真核表达载体,为探寻Trim22与HIV-1衣壳蛋白相互作用的关键结构域奠定了基础。 This study is aimed to construct eukaryotic expression vector for truncation mutants of Trim22 for further studying on the interaction of trim22 with HIV-1 gag protein.Five kinds of truncation mutants were generated by PCR with a template of eukaryotic expression vector pcDNA3.1（＋）-Trim22.Subsequently,the target sequences were subcloned into the 5-Flag-pcDNA3.1（＋）,respectivly.The recombinant vectors were confirmed by restriction enzyme digestion,PCR and DNA sequencing,and then transfected into HEK293T cells respectively.After 24 hours,the truncation mutants of Trim22 protein were detected by Western blotting and immunoprecipitation.In conclusion,the truncation mutants of Trim22 eukaryotic expression vector are constructed successfully in our study,which will benefit the future research on the effect of Trim22 against HIV-1.
作者 孙大康 宿振国 安新业 周荣佼 刘永云
机构地区 滨州医学院附属医院临床医学实验中心 滨州医学院附属医院检验科 滨州医学院附属医院研究生处
出处 《免疫学杂志》 CAS CSCD 北大核心 2011年第5期428-432,436,共6页 Immunological Journal
基金 滨州医学院科研启动基金项目(BY2010KYQD07)
关键词 三基序蛋白22 缺失突变体 艾滋病病毒 Trim22 Truncation mutants HIV-1
分类号 R346 [医药卫生—基础医学]
  • 相关文献

参考文献11

  • 1Tenzer S, Wee E, Burgevin A, et al. Antigen processing influences HIV-specific eytotoxie T lymphocyte immunodominance [J]. Nal lmmunol, 2009, 10(6):636-646.
  • 2Sebastian S, Luban J. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid [J]. Retrovirology, 2005, 2(40): doi: 10. 1186/1742-4690-2-40.
  • 3Stremlau M, Owens CM, Pert'on M J, et al. The cytoplasmic body component TRIMSalpha restricts HIV-1 infeclion in Old Worht monkeys [J].Nature, 2004, 427(6977):848-853.
  • 4Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TRIM22 [J]. PLoS Pathog, 2008, 4(2):e1000007.
  • 5McNab FW, Rajsbaum R, Stoye JP, et al. Tripartite-motif proteins and innate immune regulation [J]. Curr Opin Immunol, 2010, 23(1): 1-11.
  • 6Ozato K, Shin DM, Chang TH, et al. TRIM family proteins and their emerging roles in innate immunity [J]. Nat Rev Immunol, 2008, 8(11):849-860.
  • 7Newman RM, Hall L, Kimlaier A, et al. Evolution of a TRIM5-CypA splice isoform in old world monkeys [J]. PLoS Pathog, 2008, 4(2):e1000003.
  • 8Gao B, Duan Z, Xu W, et al. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain [J]. Hepatology, 2009, 50(2):424-433.
  • 9Kajaste Rudnitski A, Puhrone C, Marzetta F, et al. Restric-ion factors of retroviral replication: the example of Tripartite Motif (TRIM) protein 5 alpha and 22 [J]. Amino Acids, 2010, 39(1):1-9.
  • 10Herr AM, Dressel R, Walter L. Different subcellular localisations of TRIM22 suggest species-specific function [J]. Immunogenetics, 2009, 61 (4):271-280.

同被引文献13

  • 1Rajsbaum R, Garcia Sastre A, Versteeg GA. TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity[J]. J Mol Biok 2014, 426(6): 1265-1284.
  • 2Kajaste Rudnitski A, Marelli SS, Puhrone C, el al. TRIM22 inhibits HIV-1 transcription independently of its E3ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements [J]. J Virol, 2011, 85(10): 5183-5196.
  • 3Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TRIM22[J]. PLoS Pathog, 2008, 4(2): elO00007.
  • 4Yu S, Gao B, Duan Z, et aL Identification of tripartite motif-containing 22 (TRIM22) as a novel NF-kappaB activator[J]. Biochem Biophys Res Comrnun, 2011, 410(2): 247-251.
  • 5Sivaramakrishnan G, Sun Y, Rajmohan R, et al. B30.2/ SPRY domain in tripartite motif-containing 22 is essential for the formation of distinct nuclear bodies[J]. FEBS Lett, 2009, 583(12): 2093-2099.
  • 6Hatakeyama S. TRIM proteins and cancer[J]. Nat Rev Cancer, 2011, 11(11): 792-804.
  • 7Jefferies C, Wynne C, Higgs R. Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease? [J]. Nat Rev Immunol, 2011, 11(9): 617-625.
  • 8Eldin P, Papon L, Oteiza A, et al. TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activityagainst encephalomyocarditis virus [J]. J Gen Virol, 2009, 90(Pt 3): 536-545.
  • 9Gao B, Duan Z, Xu W, et al. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain [J]. Hepatology, 2009, 50(2): 424-433.
  • 10Petersson J, Ageberg M, Sanden C, et al. The p53 target gene TRIM22 directly or indirectly interacts with the translation initiation factor eIF4E and inhibits the binding of elF4E to elF4G[J]. Biol Cell, 2012, 104(8): 462-475.

引证文献1

二级引证文献2

免疫学杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部